Crimson Publishers Publish With Us Reprints e-Books Video articles


Interventions in Obesity & Diabetes

Choice of Antihyperglycemic Agents in Patients with Chronic Kidney Disease

  • Open or Close Soe Naing1* and Cho Cho Khine1, 2

    1Department of Internal Medicine, University of California, USA

    2Department of Nephrology, Veterans Affairs Central California Health Care System, USA

    *Corresponding author: Soe Naing, Associate Clinical Professor of Medicine, Director of Division of Endocrinology, Medical Director of Community Diabetes Care Center, University of California, San Francisco-Fresno Medical Education Program, Dept. of Internal Medicine, Suite A 2823 Fresno Street, Fresno, CA 93721, USA

Submission: April 04, 2018; Published: April 30, 2018

DOI: 10.31031/IOD.2018.01.000515

ISSN: 2578-0263
Volume1 Issue3


Chronic kidney disease (CKD) is one of the most frequent microvascular complications of diabetes. Approximately 40% of adults with type 2 diabetes mellitus (T2DM) have CKD and about 50% of end-stage renal disease (ESRD) is caused by diabetes [1,2]. The hypoglycemia risk is increased in patients with advanced CKD (CKD stages 4 & 5) since clearance of insulin and of some of the non-insulin antihyperglycemic agents is reduced and there is an impaired renal gluconeogenesis with reduced kidney mass [3,4].

Keywords: Chronic kidney disease; Antihyperglycemic agents; Diabetes mellitus

Get access to the full text of this article

About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137